Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
VERAPAMIL HYDROCHLORIDE TRANDOLAPRIL
Abbott Laboratories Ireland Ltd
180/2 Milligram
Modified-release Tablets
2005-08-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tarka 180 mg/2 mg modified-release tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each modified-release tablet contains 180 mg of verapamil hydrochloride and 2 mg of trandolapril. Excipient: 107 mg lactose monohydrate/modified-release tablet. For full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Modified-release tablet. Pink, oval, marked with the Knoll logo and “182” on one face. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Essential hypertension in patients whose blood pressure has been normalised with the individual components in the same proportion of doses. Refer to section 4.4 (Special warnings and precautions for use). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The usual dosage is one tablet once daily, taken in the morning before, with or after breakfast. The tablets should be swallowed whole. Children and adolescents: Tarka is contraindicated in children and adolescents (<18 years) (see also section 4.3). Elderly: As systemic availability is higher in elderly patients compared to younger hypertensives, some elderly patients might experience a more pronounced blood pressure lowering effect (see section 4.4). Renal insufficiency: Tarka is contraindicated in severe renal impairment (see section 4.3). Hepatic insufficiency: the use of Tarka is not recommended in patients with severe hepatic impairment; Tarka is contraindicated in patients with liver cirrhosis with ascites (see sections 4.3 and 4.4). 4.3 CONTRAINDICATIONS Hypersensitivity to trandolapril or any other ACE inhibitor and/or verapamil or to any of the excipients History of angioneurotic oedema associated with previous ACE inhibitor therapy Hereditary/idiopathic angioneurotic oedema Cardiogenic shock Recent myocardial infarction with Lue koko asiakirja